Payment overview · 2025
General Payments
$327.70
16 reported records · 7 companies
Healthcare provider profile · identity verified
Elving Colon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · VALDOSTA, GA · NPI 1104051119
Verified facts
What the public records show
CMS Open Payments records show Elving Colon, MD received $327.70 in general payments during 2025 across 16 reported records.
GlaxoSmithKline, LLC. accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.32 | 28.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.59 | 24.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $73.97 | 22.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.56 | 7.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.65 | 6.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.92 | 6.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.69 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $327.70 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $93.32 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $73.97 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 127 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
127 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 53 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 158 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 273 | 71 |
| Tramadol Hcl | Tramadol Hcl | 256 | 55 |
| Metformin Hcl | Metformin Hcl | 227 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 60 |
| Prednisone | Prednisone | 205 | 134 |
| Gabapentin | Gabapentin | 193 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 42 |
| Omeprazole | Omeprazole | 176 | 41 |
| Furosemide | Furosemide | 161 | 55 |
| Lisinopril | Lisinopril | 159 | 46 |
| Losartan Potassium | Losartan Potassium | 135 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 30 |
| Mounjaro | Tirzepatide | 133 | 23 |
| Trazodone Hcl | Trazodone Hcl | 131 | 30 |
| Linzess | Linaclotide | 127 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 32 |
| Famotidine | Famotidine | 115 | 31 |
| Carvedilol | Carvedilol | 110 | 27 |
| Nifedipine Er | Nifedipine | 108 | 32 |
| Glimepiride | Glimepiride | 98 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 37 |
| Sertraline Hcl | Sertraline Hcl | 88 | 20 |
| Clonazepam | Clonazepam | 85 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 23 |
| Alprazolam | Alprazolam | 73 | 13 |
| Potassium Chloride | Potassium Chloride | 69 | 23 |
| Mirtazapine | Mirtazapine | 67 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 18 |
| Eliquis | Apixaban | 66 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | suppressed |
| Lorazepam | Lorazepam | 61 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 39 |
| Januvia | Sitagliptin Phosphate | 57 | 11 |
| Meloxicam | Meloxicam | 55 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 53 |
| Simvastatin | Simvastatin | 55 | 14 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 49 | 18 |
| Azithromycin | Azithromycin | 48 | 45 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Farxiga | Dapagliflozin Propanediol | 42 | 11 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Glipizide | Glipizide | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 29 |
| Allopurinol | Allopurinol | 33 | 11 |
| Ondansetron Odt | Ondansetron | 33 | 18 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 31 | 31 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 15 |
| Ozempic | Semaglutide | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 19 |
| Atenolol | Atenolol | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 16 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Nystatin | Nystatin | 26 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Indomethacin | Indomethacin | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | 12 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $327.70 · 16 records | GlaxoSmithKline, LLC. | Auvelity, CREON, Dexcom G6 Transmitter, KISUNLA, LINZESS, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error